Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Research
Brain Tumor : Embryonal brain tumors, choroid plexus carcinoma or ependymoma
Participants in this research study are less than 3 years of age and have been diagnosed with a malignant brain tumor. Please note that Medulloblastoma patients greater than or equal to three years of age and less than 5 years of age at diagnosis who have non-metastatic disease are eligible for the study. These tumors may grow quickly. Treatments for these tumors in older children involve therapy with high doses of x-rays (radiation) to the entire brain and spinal cord. Using this type of radiation in very young children may cause permanent problems with thinking, learning, and growing.
In this study a combination of anti-cancer drugs (chemotherapy) is used to treat brain tumors in young children. Using chemotherapy gives the brain more time to develop before radiation is given. The chemotherapy in this study includes the drug methotrexate. This drug was an important part of the two clinical trials which resulted in the best survival results for children less than 3 years of age with medulloblastoma. Most patients treated on this trial will also receive radiation which is carefully targeted to the area of the tumor. This type of radiation (focal conformal radiotherapy) may result in fewer problems with thinking and learning than radiation to the whole brain and spinal cord.
An additional important goal of this research is to study the cellular biology of the brain tumors in children less than 3 years of age. Researchers hope to identify new information about the tumors that will help to define different tumor types. They would like to identify tumors that will respond to specific treatments and identify tumors that are likely to return after treatment.
For the current eligibility status of this clinical study, patient’s family, relatives and/or referring physicians may contact St. Jude Children’s Research Hospital at (901) 595-4599 or (901) 595-2544.
Amar Gajjar, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
TEL: 901-595-2544 or 901-595-4599
FAX: 901-595-5353
or
Tabatha E. Doyle, RN
Coordinator, Brain Tumor Program
Phone: 901-595-2544
Fax: 901-595-5353
Email: tabatha.doyle@stjude.org
Contact us by email anytime, 24 hours a day, 7 days a week.
The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.
